FOLD - Amicus Therapeutics, Inc.
About Amicus Therapeutics, Inc. (https://amicusrx.com)
Amicus Therapeutics, Inc., a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant based on in vitro assay data. It also develops AT-GAA, a novel treatment paradigm for Pompe disease; enzyme replacement therapies for Pompe diseases; CLN3, which is in Phase 1/2 clinical study to evaluate the safety and efficacy of a single intrathecal administration of an AAV serotype AT-GTX-502 gene therapy in patients with CLN3; and CDKL5, a gene on the X-chromosome encoding the CDKL5 protein that regulates the expression of essential proteins for normal brain development. The company has collaboration and license agreements with Nationwide Children's Hospital; University of Pennsylvania; and GlaxoSmithKline. Amicus Therapeutics, Inc. was incorporated in 2002 and is headquartered in Philadelphia, Pennsylvania.
Key Executives
| NAME | TITLE | DOB | SALARY |
|---|---|---|---|
| Bradley L. Campbell | Chief Executive Officer, President & Director | 1976 | $1,734,918 USD |
| Ellen S. Rosenberg | Chief Legal Officer & Corporate Secretary | 1964 | $985,620 USD |
| Jeffrey Castelli | Chief Development Officer | 1972 | $960,912 USD |
| Simon Nicolas Reade Harford | Chief Financial Officer | 1960 | $935,201 USD |
| David Clark | Chief People Officer | 1976 | $917,420 USD |
| Andrew Faughnan | Vice President of Investor Relations | – | – |
| Brendan McEvoy | Executive Director of External Communications | – | – |
| Jill Weimer | Chief Science Officer | – | – |
| Patrik S. Florencio | Global Chief Compliance & Risk Officer | – | – |
| Samantha Prout | Chief Accounting Officer & Controller | 1979 | – |